{"DataElement":{"publicId":"7788950","version":"1","preferredName":"Prostate Carcinoma Histologic Type","preferredDefinition":"The type of structural pattern of cancer cells used to define a diagnosis of prostate carcinoma.","longName":"7788937v1.0:7788939v1.0","context":"MCL","contextVersion":"1","DataElementConcept":{"publicId":"7788937","version":"1","preferredName":"Prostate Carcinoma Histologic Type","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease._Refers to the type of tissue in which a tumor originated.","longName":"2744055v1.0:2673286v1.0","context":"MCL","contextVersion":"1","ObjectClass":{"publicId":"2744055","version":"1","preferredName":"Prostate Carcinoma","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","longName":"C4863","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B8AEEC8-FDF2-03F8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-04-23","modifiedBy":"ONEDATA","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2673286","version":"1","preferredName":"Histologic Type","preferredDefinition":"Refers to the type of tissue in which a tumor originated.","longName":"C61478","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histologic Type","conceptCode":"C61478","definition":"Refers to the type of tissue in which a tumor originated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3820C878-7530-31CC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-20","endDate":null,"createdBy":"UMLLOADER_BCR","dateCreated":"2007-08-20","modifiedBy":"ONEDATA","dateModified":"2007-08-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"CCFFE461-A054-655E-E053-4EBD850AC8C4","latestVersionIndicator":"Yes","beginDate":"2021-09-27","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-27","modifiedBy":"COLBERTM","dateModified":"2022-02-28","changeDescription":"2/28/22 mr Released per SME.   9/27/21 mr Created for MCL prostate. Per MCL DD.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7788939","version":"1","preferredName":"Prostate Carcinoma Histologic Type","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease._Refers to the type of tissue in which a tumor originated._Something distinguishable as an identifiable class based on common qualities.","longName":"7788939v1.0","context":"MCL","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"40","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Prostatic duct adenocarcinoma","valueDescription":"Prostate Ductal Adenocarcinoma","ValueMeaning":{"publicId":"2577131","version":"1","preferredName":"Prostate Ductal Adenocarcinoma","longName":"2577131","preferredDefinition":"A usually aggressive invasive adenocarcinoma of the prostate gland composed of large glands containing tall columnar cells.  The columnar cells have abundant cytoplasm and are reminiscent of endometrial carcinoma.  This type of adenocarcinoma has a tendency to metastasize to the lung and penis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Ductal Adenocarcinoma","conceptCode":"C6813","definition":"A usually aggressive invasive adenocarcinoma of the prostate gland composed of large glands containing tall columnar cells.  The columnar cells have abundant cytoplasm and are reminiscent of endometrial carcinoma.  This type of adenocarcinoma has a tendency to metastasize to the lung and penis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA58-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-23","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"COOPERM","dateModified":"2019-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CD00BDF3-D4BB-44D3-E053-4EBD850AB8AA","beginDate":"2021-09-27","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-27","modifiedBy":"ONEDATA","dateModified":"2021-09-27","deletedIndicator":"No"},{"value":"Adenocarcinoma (conventional, NOS)","valueDescription":"Adenocarcinoma","ValueMeaning":{"publicId":"2831117","version":"1","preferredName":"Adenocarcinoma","longName":"2831117","preferredDefinition":"carcinoma derived from glandular tissue or in which tumor cells form recognizable glandular structures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"61F598EF-7D06-BDE9-E040-BB89AD43552F","latestVersionIndicator":"Yes","beginDate":"2009-02-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CD00BDF3-D4CF-44D3-E053-4EBD850AB8AA","beginDate":"2021-09-27","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-27","modifiedBy":"ONEDATA","dateModified":"2021-09-27","deletedIndicator":"No"},{"value":"Cannot be determined","valueDescription":"Cannot Be Determined","ValueMeaning":{"publicId":"7758876","version":"1","preferredName":"Cannot Be Determined","longName":"7758876","preferredDefinition":"An indication that a reason or result cannot be established.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cannot Be Determined","conceptCode":"C179711","definition":"An indication that a reason or result cannot be established.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C8BDCB33-05AB-7A20-E053-4EBD850A27B9","latestVersionIndicator":"Yes","beginDate":"2021-08-04","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-08-04","modifiedBy":"ONEDATA","dateModified":"2021-08-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CCFDB1EB-DA00-65BE-E053-4EBD850A0183","beginDate":"2021-09-27","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-27","modifiedBy":"ONEDATA","dateModified":"2021-09-27","deletedIndicator":"No"},{"value":"Not reported","valueDescription":"Not Reported","ValueMeaning":{"publicId":"2572231","version":"1","preferredName":"Not Reported","longName":"2572231","preferredDefinition":"Not provided or available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Reported","conceptCode":"C43234","definition":"Not provided or available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E734-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2004-11-16","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CCFDB1EB-D9F6-65BE-E053-4EBD850A0183","beginDate":"2021-09-27","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-27","modifiedBy":"ONEDATA","dateModified":"2021-09-27","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559666","version":"1","preferredName":"Other","longName":"2559666","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B61F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"LISU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CCFDB1EB-DA0B-65BE-E053-4EBD850A0183","beginDate":"2021-09-27","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-27","modifiedBy":"ONEDATA","dateModified":"2021-09-27","deletedIndicator":"No"},{"value":"Undifferentiated carcinoma, NOS","valueDescription":"Undifferentiated Prostate Carcinoma","ValueMeaning":{"publicId":"2577197","version":"1","preferredName":"Undifferentiated Prostate Carcinoma","longName":"2577197","preferredDefinition":"An invasive prostate carcinoma without evidence of cellular differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Undifferentiated Carcinoma","conceptCode":"C5597","definition":"An invasive prostate carcinoma characterized by the presence of undifferentiated malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA9A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"CURTIST","dateModified":"2006-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CCFDB1EB-DA1F-65BE-E053-4EBD850A0183","beginDate":"2021-09-27","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-27","modifiedBy":"ONEDATA","dateModified":"2021-09-27","deletedIndicator":"No"},{"value":"Sarcomatoid carcinoma","valueDescription":"Acinar Prostate Adenocarcinoma, Sarcomatoid Variant","ValueMeaning":{"publicId":"2577196","version":"1","preferredName":"Acinar Prostate Adenocarcinoma, Sarcomatoid Variant","longName":"2577196","preferredDefinition":"A rare morphologic variant of acinar adenocarcinoma of the prostate gland with unfavorable prognosis, composed of both malignant glandular and sarcomatous components. The sarcomatous component contains a malignant spindle cell proliferation or specific mesenchymal elements including osteosarcoma, chondrosarcoma, and leiomyosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Acinar Sarcomatoid Carcinoma","conceptCode":"C5530","definition":"A rare acinar adenocarcinoma of the prostate gland with unfavorable prognosis. It is composed of both malignant glandular and sarcomatous components. The sarcomatous component contains a malignant spindle cell proliferation or specific mesenchymal elements including osteosarcoma, chondrosarcoma, and leiomyosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA99-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-23","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"CURTIST","dateModified":"2006-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CCFDB1EB-DA34-65BE-E053-4EBD850A0183","beginDate":"2021-09-27","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-27","modifiedBy":"ONEDATA","dateModified":"2021-09-27","deletedIndicator":"No"},{"value":"Small cell carcinoma","valueDescription":"Prostate Small Cell Carcinoma","ValueMeaning":{"publicId":"2581148","version":"1","preferredName":"Prostate Small Cell Carcinoma","longName":"2581148","preferredDefinition":"A neuroendocrine carcinoma of the prostate gland with unfavorable prognosis. It is composed of small cells containing neurosecretory granules.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Small Cell Neuroendocrine Carcinoma","conceptCode":"C6766","definition":"A rare small cell neuroendocrine carcinoma that arises from the prostate gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A09-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-23","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"COOPERM","dateModified":"2020-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CCFDB1EB-DA48-65BE-E053-4EBD850A0183","beginDate":"2021-09-27","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-27","modifiedBy":"ONEDATA","dateModified":"2021-09-27","deletedIndicator":"No"},{"value":"Adenosquamous carcinoma","valueDescription":"Prostate Adenosquamous Carcinoma","ValueMeaning":{"publicId":"2577129","version":"1","preferredName":"Prostate Adenosquamous Carcinoma","longName":"2577129","preferredDefinition":"An infrequent invasive carcinoma of the prostate gland characterized by the presence of both glandular and squamous neoplastic components. It is more often located in the transitional zone of the prostate gland and it tends to rapidly metastasize to the bones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Adenosquamous Carcinoma","conceptCode":"C5538","definition":"An infrequent invasive carcinoma of the prostate gland characterized by the presence of both glandular and squamous neoplastic components.  It is more often located in the transitional zone of the prostate gland and it tends to rapidly metastasize to the bones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA56-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-23","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"DWARZEL","dateModified":"2006-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CCFDB1EB-DA5C-65BE-E053-4EBD850A0183","beginDate":"2021-09-27","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-27","modifiedBy":"ONEDATA","dateModified":"2021-09-27","deletedIndicator":"No"},{"value":"Signet-ring cell carcinoma","valueDescription":"Signet Ring Cell Carcinoma","ValueMeaning":{"publicId":"3248560","version":"1","preferredName":"Signet Ring Cell Carcinoma","longName":"3248560","preferredDefinition":"A usually aggressive, poorly differentiated invasive adenocarcinoma characterized by the presence of malignant glandular cells in which the nucleus is pressed to one side by the presence of intracytoplasmic mucus. It may arise from the stomach, small and large intestine, ampulla of Vater, appendix, gallbladder, pancreas, lung, bladder, breast, and prostate gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Signet Ring Cell Carcinoma","conceptCode":"C3774","definition":"A usually aggressive, poorly differentiated invasive adenocarcinoma characterized by the presence of malignant glandular cells in which the nucleus is pressed to one side by the presence of intracytoplasmic mucus. It may arise from the stomach, small and large intestine, ampulla of Vater, appendix, gallbladder, pancreas, lung, bladder, breast, and prostate gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6BBE041-BD41-9503-E040-BB89AD435A00","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"COOPERM","dateModified":"2011-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CCFDB1EB-DA71-65BE-E053-4EBD850A0183","beginDate":"2021-09-27","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-27","modifiedBy":"ONEDATA","dateModified":"2021-09-27","deletedIndicator":"No"},{"value":"Mucinous (colloid) adenocarcinoma","valueDescription":"Acinar Prostate Mucinous Adenocarcinoma","ValueMeaning":{"publicId":"2577198","version":"1","preferredName":"Acinar Prostate Mucinous Adenocarcinoma","longName":"2577198","preferredDefinition":"A usually aggressive morphologic variant of acinar adenocarcinoma of the prostate gland characterized by the presence of lakes of extracellular mucin. This diagnosis applies when at least 25% of the resected tumor contains extracellular mucin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Acinar Mucinous Adenocarcinoma","conceptCode":"C5537","definition":"Acinar adenocarcinoma of the prostate gland characterized by the presence of lakes of extracellular mucin. This diagnosis applies when at least 25% of the resected tumor contains extracellular mucin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA9B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-23","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"DWARZEL","dateModified":"2006-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CCFDB1EB-DA85-65BE-E053-4EBD850A0183","beginDate":"2021-09-27","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-27","modifiedBy":"ONEDATA","dateModified":"2021-09-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7788938","version":"1","preferredName":"Prostate Carcinoma Histologic Type Type","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.:Refers to the type of tissue in which a tumor originated.:Something distinguishable as an identifiable class based on common qualities.","longName":"C4863:C61478:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Histologic Type","conceptCode":"C61478","definition":"Refers to the type of tissue in which a tumor originated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CD00BDF3-D48A-44D3-E053-4EBD850AB8AA","latestVersionIndicator":"Yes","beginDate":"2021-09-27","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-27","modifiedBy":"ONEDATA","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"CD00BDF3-D49B-44D3-E053-4EBD850AB8AA","latestVersionIndicator":"Yes","beginDate":"2021-09-27","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-27","modifiedBy":"COLBERTM","dateModified":"2022-03-01","changeDescription":"9/27/21 mr Created for MCL prostate per MCL DD.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5506113","version":"1","longName":"Prostate","context":"MCL","ClassificationSchemeItems":[{"publicId":"7781145","version":"1","longName":"Prostate PCA Pilot","context":"MCL"}]},{"publicId":"6437797","version":"1","longName":"Pre-Cancer Atlas Pilot","context":"MCL","ClassificationSchemeItems":[{"publicId":"7001794","version":"1","longName":"Prostate PCA Pilot","context":"MCL"}]}],"AlternateNames":[{"name":"histologic_type","type":"MCL Alt Name","context":"MCL"}],"ReferenceDocuments":[{"name":"MCL-PCA-prostate-1","type":"Alternate Question Text","description":"Histologic type","url":null,"context":"MCL"},{"name":"MCL-Template Name","type":"Data Collection Template","description":"prostate_v0_13aug2020.xlsx","url":"https://mcl.nci.nih.gov/resources/standards/mcl-cdes","context":"MCL"},{"name":"Histologic type","type":"Preferred Question Text","description":"Histologic type","url":null,"context":"MCL"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"CD02136B-D205-6C75-E053-4EBD850A2967","latestVersionIndicator":"Yes","beginDate":"2021-09-27","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-27","modifiedBy":"COLBERTM","dateModified":"2022-02-25","changeDescription":"2/25/22 mr Released per SME.   9/27/21 mr Created for MCL prostate per MCL DD. 9/28/21 mr Added alt name, AQT, ref doc per MCL DD.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}